Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Sponsor

Biogen (Industry)

Overall Status

Completed

CT.gov ID

NCT00099489

Collaborator

(none)

Enrollment

Locations

Duration (Months)

3.4

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).

Condition or Disease	Intervention/Treatment	Phase
Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Drug: Interferon Beta-1a	Phase 2

Detailed Description

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired peripheral neuropathy of unknown origin. The etiology is not well understood but is presumed to be immunological. Evidence for this comes from observed similarities to Guillain-Barre syndrome and from the favorable response with immunomodulatory treatments.

CIDP is a peripheral nervous system demyelinating neuropathy that is sometimes a corollary disorder to the central nervous system demyelination of multiple sclerosis (MS. The precise mechanisms underlying the pathogenesis are uncertain, but a number of those mechanisms support a potential role for immunomodulatory treatments such as interferon beta (e.g., Biogen Idec Inc.'s AVONEX).

The rationale for the use of AVONEX in CIDP derives from observations on the pathogenesis of the condition and its similarities to MS, the mechanism of action of AVONEX, clinical trials that have been performed in CIDP that support a role for IFN-beta, and the unmet need that currently exists because of availability and safety issues with existing therapies.

This Phase 2b study is a dose-ranging study designed to provide scientific evidence regarding the safety and efficacy of AVONEX in CIDP. In addition, the study aims to demonstrate the responsiveness and clinical relevance of changes in the MRC sum score and ODSS in CIDP patients.

Study Design

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Study Start Date :

Feb 1, 2004

Actual Primary Completion Date :

Feb 1, 2006

Actual Study Completion Date :

Feb 1, 2006

Outcome Measures

Primary Outcome Measures

The primary endpoint for the efficacy analyses is the total IVIg dose (g/Kg) administered after Visit 5 and through Visit 9 (Week 32, End of Study). []

Secondary Outcome Measures

The time to disease progression. []
Percentage reduction in IVIg dose (g/Kg). []
The number of days between Visit 5 and either disease progression or Visit 9 []
(Week 32, End of Study). []
The proportion of subjects with disease progression at Visit 9 (Week 32, End of Study). []
The change in MRC sum score from baseline to the time of IVIg withdrawal. []
Change from baseline to Visit 5 and to Visit 9 (Week 32, End of Study) in a composite score of maximal conduction velocity. []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent prior to any testing under this protocol
Must be between 18 and 75 years of age
Have a diagnosis of CIDP as determined by a board-certified or board-eligible neurologist, or equivalent, for at least 6 months, including fulfilling modified INCAT neurophysiological criteria for CIDP,CIDP motor deficit responsive to IVIg and alternative EP data that justifies subject inclusion, and/or supportive pathologic or laboratory data that supports the diagnosis of CIDP
Documentation in the medical record prior to screening that the CIDP had been associated with loss of muscle strength, such that the MRC sum score was less than or equal to 58.
Documentation in the medical record that the patient benefited fom IVIg treatment (patient had a 2-point change or equivalent in 60-point MRC sum score)
Tested for IgM monoclonal gammopathy and found to have tested negative for IgM monoclonal gammopathy or if positive for IgM monoclonal gammopathy, then are MAG antibody-negative and proven to be IVI g responsive per protocol.
Must have been clinically stable while on a constant regimen of IVIg (every 2-weeks, 3-weeks, 4-weeks or 5-weeks) in the 3 months prior to screening.

Exclusion Criteria*:

Associated systemic disorder that might cause neuropathy.
History of, or abnormal laboratory results indicative of any significant major disease or known drug hypersensitivity that, in the opinion of the investigator, would preclude the administration if IFN-beta or participation in this study.
Subjects with diabetes mellitus will not be eligible, unless they satisfy both of the following requirements: a) their diabetes is well-controlled, with no retinopathy or nephropathy, having been identified during the ongoing care of their diabetes; and b) they have a normal sensory nerve action potential (SNAP) amplitude recorded in the sural nerve on at least one side of the body identified during electrophysiology (EP) testing documented in their medical record.
Abnormal screening or baseline blood tests that the investigator deems clinically significant
History of a seizure disorder prior to baseline (Visit 1, Week 0).
History of suicidal ideation within 3 months prior to Baseline Visit (Week 0) or an episode of severe depression within 3 months prior to Baseline Visit (Week 0).
Pure motor syndrome fulfilling criteria for multifocal motor neuropathy with conduction block.
Pure sensory CIDP, or any other variant of CIDP without motor involvement
Serious local infection or systemic infection within the 6 months prior to Screening.
Use of IFN-beta at any time, use of plasma exchange, plasmapheresis, or any other immunosuppressant (with the exception of oral or non-systemic corticosteroids) within 6 months prior to Screening.
History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, and/or aspirin that would preclude use of at least one of these during the study.
For female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the Investigator, during the study.
Female subjects considering becoming pregnant while in the study
Female subjects who are currently pregnant or breast-feeding.
This list is not exhaustive and there may be additional exclusions

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Phoenix Neurological Associates, Ltd.	Phoenix	Arizona	United States	85006
2	Neuromuscular Research Center	Scottsdale	Arizona	United States	85258
3	University of Florida, Jacksonville	Jacksonville	Florida	United States	32209
4	University of Miami	Miami	Florida	United States	33136
5	University of Kansas	Kansas City	Kansas	United States	66160
6	Louisiana State University	New Orleans	Louisiana	United States	70112
7	Harvard University/MGH	Boston	Massachusetts	United States	02114
8	Tufts University/ St. Elizabeths	Boston	Massachusetts	United States	02135
9	University of Minnesota	Minneapolis	Minnesota	United States	55455
10	Weill Medical College of Cornell University	New York	New York	United States	10022
11	Raleigh Neurology Associates	Raleigh	North Carolina	United States	27607
12	University of Texas Southwestern	Dallas	Texas	United States	75390-8897
13	University of Utah	Salt Lake City	Utah	United States	84132
14	Liverpool Hospital	Liverpool	New South Wales	Australia	2170
15	Institute of Clinical Neurosciences	Sydney	New South Wales	Australia	2006
16	St. Vincent's Hospital	Fitzroy	Victoria	Australia	3065
17	Royal Melbourne Hospital	Parkville	Victoria	Australia	3050
18	London Health Sciences Center	London	Ontario	Canada	N6A 5A5
19	Montreal Neurological Hospital	Montreal	Quebec	Canada	H3A 2B4
20	Guy's Hospital/Dept. of Neuroimmunology	London		United Kingdom	SE1 1UL